A meta-analysis that included five randomized controlled trials showed that GO treatment improved the risk of relapse and 5-year OS in CBF-AML patients, with a definite survival advantage for CBF-AML patients with GO treatment compared to those without GO treatment(OR = 0.47, 95%CI:0.31–0.73, P < 0.001) [29–33]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.